间充质干细胞移植,非甾体类抗炎 z-bo 2020-09-30 357

　　In high-income countries, non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most important causes of peptic ulcer disease. Proton pump inhibitors are currently the standard treatment for this peptic ulcer disease. However, in recent years, the safety and long-term side effects of using proton pump inhibitors have received increasing attention.

　　In a new study, researchers from the Chinese University of Hong Kong and the First Hospital of the University of Science and Technology of China developed a pig model of NSAID-related gastric ulcer and compared it with conventional saline injection. Submucosal injection of adipose-derived mesenchymal stem cells (ADMSC) through an endoscope (as a control) rapidly promoted ulcer healing on the 7th and 21st days, thereby reducing and enhancing inflammation. Epithelialization (re-epithelization) and new angiogenesis. However, few transplanted ADMSCs show myofibroblast and epithelial cell phenotypes in vivo, and the ulcer healing process is less dependent on stem cell differentiation. It is possible. Further experiments showed that the therapeutic effect of submucosal injection of the secretome derived from mesenchymal stem cells (MSC) is comparable to that of MSC transplantation.

　　Through analysis, these researchers found that genes related to inflammation, granulation formation and extracellular matrix remodeling were upregulated 7 days after injection of MSC-derived secretin.

　　In addition, after injection of ADMSC or MSC-derived secretome, the extracellular signal-regulated kinase/mitogen-activated protein kinase (MAPK) and phosphoinositide-3-kinase/protein kinase B (PI3K/PKB) pathways are activated. Both of these signaling pathways are involved in mediating key events important for the healing of gastric ulcers, such as cell survival, cell migration, and angiogenesis. These data indicate that submucosal injection of ADMSC under endoscope is a promising method to accelerate the healing of NSAID-related peptic ulcers, during which these stem cells release paraclinical cell effectors. Show that it worked.